ConvaTec Group PLC
SWB:2CV
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2.48
3.42
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
ConvaTec Group PLC
ConvaTec Group PLC is a notable player in the realm of medical products and technologies, deftly weaving its narrative within the healthcare industry. Founded in 1978, the company has steadily established itself through strategic expansion and innovation, focusing on improving the lives of patients and enhancing healthcare delivery. The company's core business revolves around four main product categories: Advanced Wound Care, Ostomy Care, Continence and Critical Care, and Infusion Care. Each of these sectors is backed by a robust commitment to research and development, allowing ConvaTec to deliver specialized products that cater to both specific patient needs and broader healthcare system demands.
ConvaTec's financial model centers around providing essential, high-quality medical solutions that ultimately support improved patient outcomes. The company garners revenue by partnering with hospitals, healthcare providers, and direct consumer channels, ensuring its products reach where they are most needed. With a global footprint spanning multiple continents, ConvaTec not only distributes its products widely but also adapts its strategy to meet the nuanced requirements of diverse markets. By aligning itself closely with caregivers and leveraging cutting-edge technology, the company maintains a sustainable economic engine through both recurring sales from consumables and long-term relationships with its institutional clients.
ConvaTec Group PLC is a notable player in the realm of medical products and technologies, deftly weaving its narrative within the healthcare industry. Founded in 1978, the company has steadily established itself through strategic expansion and innovation, focusing on improving the lives of patients and enhancing healthcare delivery. The company's core business revolves around four main product categories: Advanced Wound Care, Ostomy Care, Continence and Critical Care, and Infusion Care. Each of these sectors is backed by a robust commitment to research and development, allowing ConvaTec to deliver specialized products that cater to both specific patient needs and broader healthcare system demands.
ConvaTec's financial model centers around providing essential, high-quality medical solutions that ultimately support improved patient outcomes. The company garners revenue by partnering with hospitals, healthcare providers, and direct consumer channels, ensuring its products reach where they are most needed. With a global footprint spanning multiple continents, ConvaTec not only distributes its products widely but also adapts its strategy to meet the nuanced requirements of diverse markets. By aligning itself closely with caregivers and leveraging cutting-edge technology, the company maintains a sustainable economic engine through both recurring sales from consumables and long-term relationships with its institutional clients.
Strong Sales Growth: ConvaTec delivered 8% constant currency growth and 6.4% organic revenue growth in the first half of 2022, with all four categories contributing.
Margins Hold Up: EBIT margin was 19.6%, stable year-on-year despite inflation and higher investment in R&D and sales/marketing.
Guidance Unchanged: Management reaffirmed full-year guidance for 4%–5.5% organic sales growth and at least 18% EBIT margin (constant currency), despite increased cost pressures.
Operational Efficiency: Ongoing focus on simplification and efficiency led to G&A expenses dropping below 10% of sales for the first time.
Strong Cash Generation: Robust cash flow enabled continued investment in growth, including $179 million in M&A during H1.
Product Pipeline: New product launches and acquisitions (e.g., Triad Life Sciences) are expected to support future growth and margin improvement.
Supply Chain Resilience: Management reported a stronger and more resilient supply chain, aided by increased inventory and automation investments.
Mid-Term Margin Ambition: Leadership reiterated confidence in growing EBIT margin to the mid-20% range over time.
